FFEI launch Sierra Validate & Standardise Analyser.
A digital colour validation tool for Digital Pathology scanning devices that identifies the variances between the digital colours produced and actual ground-truth colour.
November 23rd, 2020 – FFEI Ltd, the global developer of award-winning digital imaging solutions, today announced the launch of Sierra Validate & Standardise (VS) Analyser, the latest product available within the patented Sierra colour calibration technology portfolio. The first of its kind available on the market, Sierra VS-Analyser enables digital pathologists, toxicologic specialists, QA technicians and software developers to make informed decisions on the digital pathology equipment and related workflow utilised.
For organisations and professionals in the fields of digital pathology and pharmaceutical development, adhering to process control for quality and regulatory purposes is paramount. They are increasingly reliant on Whole Slide Imaging (WSI) devices for accurate diagnosis and multi-location drug toxicologic pathology – both with life changing implications.
With such a wide range of scanning devices on the market, one of the most common issues users need to address is the variation in colour that different devices can create. Often viewed as a ‘blackbox’, WSI devices have many aspects which can affect their ability to output images that represent ‘ground-truth colour’. Having the ability to measure and understand these characteristics becomes essential when good process control is needed.
The Sierra VS-Analyser package consists of a validation and analysis software tool that accompanies a Sierra Calibration Slide, providing a ground-truth pathology colour reference with tissue scanning characteristics. The analysis tool validates the colour reproducibility of a digital pathology scanner for a wide range of common and special stains and reveals the degree of standardisation across a portfolio of scanning devices. This enables a full appreciation of any variances from ground-truth histological colour that are inherited by current non-standardised tissue images.
Speaking on the importance of Sierra VS-Analyser Andy Cook, CEO at FFEI, commented “With many laboratories moving into digital imaging, it is essential that users understand the colour performance of their imaging devices to ensure quality decisions can be made either by humans or artificial intelligence. For pathologists and data scientists alike, it’s often critical to confirm that the digital images produced are truly representative of the real tissue slide.” Cook continues, “Sierra VS-Analyser helps to answer these questions.”
FFEI is launching the new Sierra VS-Analyser product at the Digital Pathology & AI Congress in December, where Rick Salmon, Business Development Lead – Life Science Technologies, will be presenting on the subject of “The Impact of Validating and Standardising Ground-truth Colour for WSI”.